Related references
Note: Only part of the references are listed.Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Ahmed F. Salem et al.
PHARMACEUTICALS (2020)
Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
Ahmed F. Salem et al.
CANCERS (2020)
Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Nune Markosyan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Design and synthesis of small molecule agonists of EphA2 receptor
Aaron Petty et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate
Ahmed F. Salem et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice
Claudio Festuccia et al.
Oncotarget (2018)
Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell
Luca Gambini et al.
ACS CHEMICAL BIOLOGY (2018)
The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures
Deo R. Singh et al.
COMMUNICATIONS BIOLOGY (2018)
Targeting Eph/ephrin system in cancer therapy
Alessio Lodola et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
W. Song et al.
ONCOGENE (2017)
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
Jun Hasegawa et al.
CANCER BIOLOGY & THERAPY (2016)
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine
Bridget A. Quinn et al.
ONCOTARGET (2016)
Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells
Bainan Wu et al.
CHEMISTRY & BIOLOGY (2015)
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists
Massimiliano Tognolini et al.
CHEMMEDCHEM (2014)
Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System
Elisa Barile et al.
CHEMMEDCHEM (2014)
Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells
Si Wang et al.
CLINICAL CANCER RESEARCH (2013)
Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor
Matteo Incerti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor
Simonetta Russo et al.
MOLECULES (2013)
Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5
Kai Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor
Srinivas Duggineni et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Si Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Emerging strategies for EphA2 receptor targeting for cancer therapeutics
Manish Tandon et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Structure-Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor
Sayantan Mitra et al.
BIOCHEMISTRY (2010)
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
Leonardo Faoro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Eph-ephrin bidirectional signaling comes into the context of lymphocyte transendothelial migration
Eva M. Trinidad et al.
CELL ADHESION & MIGRATION (2010)
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Elena B. Pasquale
NATURE REVIEWS CANCER (2010)
EphA2 as a promoter of melanoma tumorigenicity
Naira V. Margaryan et al.
CANCER BIOLOGY & THERAPY (2009)
Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients
Wei-Jie Yuan et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer
Helenia Ansuini et al.
JOURNAL OF ONCOLOGY (2009)
EphA2 overexpression is associated with angiogenesis in ovarian cancer
Yvonne G. Lin et al.
CANCER (2007)
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma
William M. Merritt et al.
CANCER BIOLOGY & THERAPY (2006)
Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder
S Abraham et al.
CLINICAL CANCER RESEARCH (2006)
Whole-body imaging with fluorescent proteins
Robert M. Hoffman et al.
NATURE PROTOCOLS (2006)
EphA2 as a target for ovarian cancer therapy
CN Landen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
EphA2 as a novel molecular marker and target in glioblastoma multiforme
J Wykosky et al.
MOLECULAR CANCER RESEARCH (2005)
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics
RC Ireton et al.
CURRENT CANCER DRUG TARGETS (2005)
被撤回的出版物: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma (Retracted article. See FEB, 2023)
MS Duxbury et al.
ONCOGENE (2004)
Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness
MS Duxbury et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma
T Miyazaki et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia
GY Zeng et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
An ephrin mimetic peptide that selectively targets the EphA2 receptor
M Koolpe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization
K Ogawa et al.
ONCOGENE (2000)
Share Paper
